As much as $154.9 million in cash gained from the sale of its sequencing subsidiary, 454 Life Sciences, to Roche Diagnostics Corp. will help CuraGen Corp. get at least one cancer drug into Phase III trials by next year - not a bad return for the $36.1 million investment made when 454 was founded. (BioWorld Today)